Pharmaceuticals group Trinity Biotech has reported strong growth in the three months to the end of September, with after-tax profits up 43 per cent to $1.74 million. Sales for the period rose 15 per cent to $7.6 million.

In the first nine months of the year, after-tax profits rose 47 per cent to $4.7 million while sales rose 12 per cent to $21.9 million. At the end of September, the group had net cash of $6.1 million.